Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with…
Participants canregister herefor the virtual event airing 9:00am ET / 3:00pm CETPARIS and CAMBRIDGE, Mass., Dec.17, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "Accelerating the Future of Nanotherapeutics,"...
Nasdaq GlobeNewswire
17/12/2024
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare…
About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our…
PR Newswire
17/12/2024
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Daix (France), New York City (New York, United States), December 17, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of...
Nasdaq GlobeNewswire
17/12/2024
Global Market for Drug-Device Combinations to Reach $200 Billion by End of 2029
Drug-device combinations combine pharmaceutical drugs with medical devices to improve the effectiveness of treatments and convenience for patients. This report provides a thorough analysis of the market for drug-device combinations, analyzing trends from 2021, estimates for 2024, and projections from 2024 to 2029. Drug-device combinations combine pharmaceutical drugs with medical devices to improve the effectiveness of treatments and convenience for patients. This report provides a thorough...
PR Newswire
17/12/2024
Key information relating to the potential subsequent repair offering to be…
Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS ("Zelluna"), the fully committed private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering") of up to 3,846,153 new shares at a subscription price per new share of NOK 2.60…
Nasdaq GlobeNewswire
17/12/2024
Ultimovacs ASA – Mandatory notification of trade
Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement" and together with the Business Combination, the "Transactions"). Please see the attached forms for information on the conditional allocation of shares in the Company to closely…
Nasdaq GlobeNewswire
17/12/2024
AB Science provides a summary of the webcast held on December 16, 2024
PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON AB8939, A NOVEL MICROTUBULE DESTABILIZER ESCAPING MULTIDRUG RESISTANCE AND STEM CELL TARGETED ALDH INHIBITOR, CURRENTLY IN PHASE 1Paris, 17 December 2024, 7pm CETAB Science SA(Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML).The webcast presentation is available on the company's website, in the section « Press Releases »: ...
Nasdaq GlobeNewswire
17/12/2024
ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Ultimovacs ASA (OSE: ULTI) ("Ultimovacs" or the "Company") and Zelluna Immunotherapy AS ("Zelluna"), a privately held company pioneering the development of “off the shelf” T- Cell Receptor Natural Killer (TCR-NK) cell therapies for the treatment of…
Nasdaq GlobeNewswire
17/12/2024
Pharmaceutical Filtration Market to Hit USD 20.97 Billion by 2029 with 9.5% CAGR…
Browse in-depth TOC on "Pharmaceutical Filtration Market" Browse in-depth TOC on "Pharmaceutical Filtration Market" 944 - Tables 60 - Figures 645 - Pages Based on type,the pharmaceutical filtration market is segmented into sterile filtration and non-sterile filtration. The sterile filtration segment accounted for the largest share of the pharmaceutical filtration market. This can be owing to increasing demand for biologics drugs and rising research and development...
PR Newswire
17/12/2024
Artificial Intelligence in Clinical Trials Market to Hit US$ 2.74 Billion by…
Browse in-depth TOC on "Artificial Intelligence in Clinical Trials Market" Browse in-depth TOC on "Artificial Intelligence in Clinical Trials Market" 250 - Tables 50 - Figures 300 - Pages Another driver is the high cost of clinical trials, which AI can reduce by predicting outcomes and coming in to optimize the design of such trials. Using AI, companies can simulate trial scenarios by assessing their potential risks, minimizing the cost of trials, and increasing the…
PR Newswire
17/12/2024
Zentiva hosted the "European Health Check":
With generics accounting for 70% of medicines in Europe, including 9 out of 10 medicines on the critical medicines list, these treatments form the backbone of public health, yet they face mounting challenges. With generics accounting for 70% of medicines inEurope, including 9 out of 10 medicines on the critical medicines list, these treatments form the backbone of public health, yet they face mounting challenges. "Generic medicines are the cornerstone ofEurope'shealthcare system, but...
PR Newswire
17/12/2024
Evaxion pursues agreement with EIB to bolster equity through conversion of debt…
Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion's €7 million loan with EIB into an equity-type instrumentSuch conversion is expected to increase Evaxion's equity by $3.7 million immediately upon completionThe conversion would significantly enhance Evaxion's equity and capital structure. As such, it is an important part of Evaxion's plan on ensuring ongoing compliance with the Nasdaq listing requirements An...
Nasdaq GlobeNewswire
17/12/2024
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results…
Teva hosting investor call today at 8:00 a.m. ET (U.S.) Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussionsPARSIPPANY, N.J. and PARIS, Dec.17, 2024(GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S...
Nasdaq GlobeNewswire
17/12/2024
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class…
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's diseasePrimary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussionsProgram underscores Sanofi's...
Nasdaq GlobeNewswire
17/12/2024
BRITISH BEAUTY WEEK 2025: NATIONWIDE CELEBRATION OF £27.2BN BEAUTY INDUSTRY…
With the Council spotlighting the power of the sector to propel innovation cross-industry, British Beauty Week will bring industry together to celebrate cutting edge design, future-facing tech solutions, the power of the next generation for driving change and more. With the Council spotlighting the power of the sector to propel innovation cross-industry, British Beauty Week will bring industry together to celebrate cutting edge design, future-facing tech solutions, the power of the next...
PR Newswire
17/12/2024
/C O R R E C T I O N -- North Six/
Former Executive Director of Dazed Studio, Liam Osbourne, and former Global Head of Strategy of FLUX at Monks, Duncan Gowers, have been onboarded to North Six as Global SVP Clients & Growth and Global SVP Strategy, respectively. They will work closely with US VP of Experiential Andrew Barlow, and UK-based Head of Experiential Liam Leslie, along with Mikey O'Brien, North Six VP of Consumer Influence. Jointly, the team will lead the growth of the new business in the UK and US. Former…
PR Newswire
17/12/2024
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in…
BioVaxys' DPX™ technology ("DPX"), is a patented delivery platform that can package/deliver a range of bioactive molecules, such as mRNA/polynucleotides, peptides/proteins, virus-like particles, and small molecules, to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform, which is non-aqueous and non-systemic, facilitates immune cell recruitment and antigen uptake at the injection site for delivery to regional lymph nodes via…
PR Newswire
17/12/2024
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease…
Alzheimer's disease represents an almost insurmountable global health challenge, affecting millions worldwide with few treatment options available. Tiziana's novel approach focuses on reducing inflammation in the brain by addressing one of the major underlying inflammatory mechanisms believed to contribute to disease progression.Foralumab delivered intranasally, offers a unique mechanism of action by reducing brain microglial inflammation in patients with Alzheimer's disease. This...
Nasdaq GlobeNewswire
17/12/2024
In-Depth Market Analysis of Rare Autoimmune Disorders: Myasthenia Gravis…
The market is also witnessing the emergence of precision medicine, allowing for personalized treatment plans based on genetic and molecular profiling. Additionally, regulatory bodies are fast-tracking approvals for orphan drugs, fostering innovation, and enhancing access to life-saving treatments for patients with rare autoimmune conditions. The market is also witnessing the emergence of precision medicine, allowing for personalized treatment plans based on genetic and molecular profiling...
PR Newswire
17/12/2024
Change to Novonesis' Board of Directors
Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. Cees de Jong, Chairman of the Board, comments:“Sharon James joined legacy Novozymes' Board of Directors in 2020. She has made significant contributions to Novozymes, now Novonesis, shaping the organization's direction. As leader of the...
Nasdaq GlobeNewswire
17/12/2024
Robertshaw Confirms Its European Commitment After Slovakia Plant Sale
Selling the plant was in the best interest of the Company and its 130 Trnava plant employees, who, through the sale, were able to maintain their plant employment. Robertshaw sincerely appreciates those employees' hard work, expertise and professionalism and is gratified they could secure positions with the plant's new ownership. Selling the plant was in the best interest of the Company and its 130 Trnava plant employees, who, through the sale, were able to maintain their plant employment...
PR Newswire
17/12/2024
University of Hartford adopts Sectra's service to improve education and speed up…
Daniel DeMaio, Director of the University's Radiologic Technology program, says: "This new platform will be an exciting new resource for our radiologic technology students. The field is already highly competitive, and our students enjoy nearly 100 percent job placement within 12 months of graduation. With Sectra's education portal, we can complement time spent in the hospital with effective, interactive, digital studying ensuring that students have the experience they need to succeed."…
PR Newswire
17/12/2024
Implantica deepens market penetration in Italy with the addition of the ninth…
Dr. Sitzmann says, "It's exciting to be at the start of a revolution in the surgical treatment of GERD with RefluxStop™ leading the way. With RefluxStop™, I can offer the benefits of a durable surgical treatment to many more chronic GERD patients looking for an innovative solution to minimize their side effects and significantly improve their quality of life. This is sure to have a significant positive impact on the lives of GERD patients in our Dolomite Mountain community." Dr…
PR Newswire
17/12/2024
Orexo enters into collaboration with Abera to develop nasal powder vaccines…
As a first step, the aim is to develop powder-based intranasal vaccine candidates, focusing on Abera's influenza vaccine candidate. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. As a first step, the aim is to develop powder-based intranasal vaccine candidates, focusing on Abera's influenza vaccine candidate. An intranasal influenza vaccine...
PR Newswire
17/12/2024
Altri Comunicati
